Travere patent expiration

1. Filspari patent expiration

FILSPARI's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9993461 TRAVERE Method for treating disorders associated with glomerular function
Mar, 2030

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 17, 2028
Orphan Drug Exclusivity(ODE-389) Feb 17, 2030

Drugs and Companies using SPARSENTAN ingredient

NCE-1 date: 17 February, 2027

Market Authorisation Date: 17 February, 2023

Treatment: Treatment of primary immunoglobulin a nephropathy (igan) in adults at risk of rapid disease progression

Dosage: TABLET

More Information on Dosage

FILSPARI family patents

Family Patents